Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Rajesh Venkitakrishnan, MD, dnb, Prasanna Kumar Thomas, MD, Ankit Bansal, MD, dnb, Indranath Ghosh, MD, Jolsana Augustine, dtcd, dnb, R. Divya, md & Melcy Cleetus, dtcd, dnb. (2022) Fluticasone/formoterol compared with other ICS/LABAs in asthma: a systematic review. Journal of Asthma 59:6, pages 1221-1230.
Read now
Read now
Satish Chandra Kilaru, Avya Gopal Bansal, Vaishali Sandeep Naik, Meena Lopez & Jaideep Ashok Gogtay. (2022) A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination. Expert Review of Respiratory Medicine 16:5, pages 529-540.
Read now
Read now
Sebastien Boisseau, Murtaza Qasuri, Weng Tong Ho, Wrik Ghosh & Yacine Hadjiat. (2020) Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore. ClinicoEconomics and Outcomes Research 12, pages 567-577.
Read now
Read now
Ying Tang, Caiyun Zhang, Zhigang Zhang & Jinhui Tian. (2019) The efficacy and safety of different long-acting β2-agonists combined with inhaled glucocorticoid regimens in patients with asthma: a network meta-analysis. Journal of Asthma 56:11, pages 1159-1171.
Read now
Read now
A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik, Z Koroknai, K McAulay, S Mersmann, PS Dalvi & T Overend. (2017) Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1961-1971.
Read now
Read now
Hiroshi Chantaphakul & Kiat Ruxrungtham. (2016) Fixed-Dose combination of the inhaled corticosteroid and long-acting beta2-agonist therapy in adults with persistent asthma. Expert Opinion on Pharmacotherapy 17:5, pages 631-642.
Read now
Read now
Theresa R Prosser & Suzanne G Bollmeier. (2015) Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma. Therapeutics and Clinical Risk Management 11, pages 889-899.
Read now
Read now
Ricardo Antonio Tan & Jonathan Corren. (2014) Clinical utility and development of the fluticasone/formoterol combination formulation (Flutiform®) for the treatment of asthma. Drug Design, Development and Therapy 8, pages 1555-1561.
Read now
Read now
David Price & Elizabeth V Hillyer. (2014) Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma. Expert Review of Respiratory Medicine 8:3, pages 275-291.
Read now
Read now
Articles from other publishers (34)
Yuji Oba, Sumayya Anwer, Tarang Patel, Tinashe Maduke & Sofia Dias. (2023) Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2023:8.
Crossref
Crossref
Sanjeeva Dissanayake, Gill MundinJo WoodwardMark LomaxPrashant Dalvi. (2023) Pharmacokinetic and Pharmacodynamic Comparison of Fluticasone Propionate/Formoterol Fumarate Administered via a Pressurized Metered-Dose Inhaler and a Novel Breath-Actuated Inhaler in Healthy Volunteers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 36:2, pages 65-75.
Crossref
Crossref
Yuji Oba, Sumayya Anwer, Tinashe Maduke, Tarang Patel & Sofia Dias. (2022) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews 2022:12.
Crossref
Crossref
Ralph Brattsand & Olof Selroos. (2022) May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?. Pulmonary Pharmacology & Therapeutics 77, pages 102167.
Crossref
Crossref
Kittipong Maneechotesuwan, Dave Singh, Leandro G. Fritscher, Nese Dursunoglu, Abhijith P.G.Abhay Phansalkar, Bhumika Aggarwal, Emilio Pizzichini, Justyna Chorazy & Heather Burnett. (2022) Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis. Respiratory Medicine 203, pages 106993.
Crossref
Crossref
Ashraf Elsayed Sileem, Ahmed Ali, Hanan Elnahas & Ahmed M. Gouda. (2021) Comparing the Asthma Control and Anti-inflammatory Effects of Different Fixed Combinations of Inhaled Corticosteroids Plus Long-acting Beta 2 Agonist; A Randomized Clinical Trial. Open Access Macedonian Journal of Medical Sciences 9:B, pages 771-778.
Crossref
Crossref
Yee Vern Yong, Siti Hajar Mahamad Dom, Nurulmaya Ahmad Sa’ad, Rosliza Lajis, Faridah Aryani Md. Yusof & Jamalul Azizi Abdul Rahaman. (2021) Development and Practical Application of a Multiple-Criteria Decision Analysis Framework on Respiratory Inhalers: Is It Always Useful in the MOH Malaysia Medicines Formulary Listing Context?. MDM Policy & Practice 6:1, pages 238146832199406.
Crossref
Crossref
V. Rajesh, Jolsana Augustine, R. Divya & Melcy Cleetus. (2020) Inhaled Formoterol-Fluticasone Single Inhaler Therapy in Asthma: Real-World Efficacy, Budget Impact, and Potential to Improve Adherence. Canadian Respiratory Journal 2020, pages 1-8.
Crossref
Crossref
Renzheng Guan, Yanli Liu, Dunqiang Ren, Jinfeng Li, Tao Xu & Haiyan Hu. (2019) The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis. Journal of International Medical Research 48:3, pages 030006051988944.
Crossref
Crossref
Seong-Dae Woo, Young-Min Ye, Youngsoo Lee, So-Hee Lee, Yoo Seob Shin, Joo Hun ParkHyunna ChoiHyun-Young LeeHyun-Jung ShinHae-Sim Park. (2020) Efficacy and Safety of a Pressurized Metered-Dose Inhaler in Older Asthmatics: Comparison to a Dry Powder Inhaler in a 12-Week Randomized Trial. Allergy, Asthma & Immunology Research 12:3, pages 454.
Crossref
Crossref
David B. Price, Victoria Carter, Jessica Martin, Elizabeth A. Gardener, Derek Skinner, Sen Yang, Matthias Hoffman, Jenna C. Willis & Andrew J. Cooper. (2019) Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β2-Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care. Drugs 80:1, pages 47-60.
Crossref
Crossref
Dominik Kappeler, Knut Sommerer, Claudius Kietzig, Bärbel Huber, Jo Woodward, Mark Lomax & Prashant Dalvi. (2018) Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler. Respiratory Medicine 138, pages 107-114.
Crossref
Crossref
Akash Balki, S. Balamurugan, Suhas Bardapurkar, Sonia Dalal, Ajeet Singh, B.P. Singh, Abhijit Vaidya & Jaideep A. Gogtay. (2018) Comparison of fluticasone/formoterol with budesonide/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial. Pulmonary Pharmacology & Therapeutics 48, pages 28-36.
Crossref
Crossref
Vibeke Backer, Adam Ellery, Sylvia Borzova, Stephen Lane, Magda Kleiberova, Peter Bengtsson, Tadeusz Tomala, Dominique Basset-Stheme, Carla Bennett, Dirk Lindner, Arthur Meiners & Tim Overend. (2018) Non-interventional study of the safety and effectiveness of fluticasone propionate/formoterol fumarate in real-world asthma management. Therapeutic Advances in Respiratory Disease 12, pages 175346661879698.
Crossref
Crossref
Anna Płoszczuk, Miroslava Bosheva, Kay Spooner, Tammy McIver & Sanjeeva Dissanayake. (2018) Efficacy and safety of fluticasone propionate/formoterol fumarate in pediatric asthma patients: a randomized controlled trial. Therapeutic Advances in Respiratory Disease 12, pages 175346661877792.
Crossref
Crossref
David BellLucielle MansfieldMark Lomax. (2017) A Randomized, Crossover Trial Evaluating Patient Handling, Preference, and Ease of Use of the Fluticasone Propionate/Formoterol Breath-Triggered Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery 30:6, pages 425-434.
Crossref
Crossref
O. Schmidt, W. Petro, G. Hoheisel, F. Kanniess, P. Oepen & B. Langer-Brauburger. (2017) Real-life effectiveness of asthma treatment with a fixed-dose fluticasone/formoterol pressurised metered-dose inhaler – Results from a non-interventional study. Respiratory Medicine 131, pages 166-174.
Crossref
Crossref
Fabio Arpinelli, Mauro Carone, Gioacchino Riccardo & Giorgio Bertolotti. (2016) Health-related quality of life measurement in asthma and chronic obstructive pulmonary disease: review of the 2009-2014 literature. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Eva Martínez Moragón, Julio Delgado, Pedro Ojeda, Luis Pérez del Llano, Juan Manuel Collar, Cristina Antón-Rodriguez & Carlos Martín-Saborido. (2016) Economic Evaluation of Fluticasone Propionate/Formoterol (Flutiform®) vs. Fluticasone/Salmeterol and Budesonide/Formoterol in Spain. Pulmonary Therapy 2:2, pages 199-213.
Crossref
Crossref
Andrzej Emeryk, Rabih Klink, Tammy McIver & Prashant Dalvi. (2016) A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma. Therapeutic Advances in Respiratory Disease 10:4, pages 324-337.
Crossref
Crossref
Alberto PapiAdel H. MansurTetyana PertsevaKirsten KaiserTammy McIverBirgit GrotheSanjeeva Dissanayake. (2016) Long-Term Fluticasone Propionate/Formoterol Fumarate Combination Therapy Is Associated with a Low Incidence of Severe Asthma Exacerbations. Journal of Aerosol Medicine and Pulmonary Drug Delivery 29:4, pages 346-361.
Crossref
Crossref
René Aalbers, Claus Vogelmeier & Piotr Kuna. (2016) Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respiratory Medicine 111, pages 1-7.
Crossref
Crossref
J.A. Quintano Jiménez, L. Ginel Mendoza, L.M. Entrenas Costa & J. Polo García. (2016) Combinación a dosis fija de fluticasona propionato/formoterol fumarato para el tratamiento del asma: una revisión de la farmacología, eficacia y tolerabilidad. SEMERGEN - Medicina de Familia 42, pages 2-9.
Crossref
Crossref
M. Latorre, P. Paggiaro, W. Canonica, M.P. Foschino & A. Papi. (2015) A valid option for asthma control: Clinical evidence on efficacy and safety of fluticasone propionate/formoterol combination in a single inhaler. Pulmonary Pharmacology & Therapeutics 34, pages 31-36.
Crossref
Crossref
William C. AndersonIIIIII & Stanley J. Szefler. (2015) New and future strategies to improve asthma control in children. Journal of Allergy and Clinical Immunology 136:4, pages 848-859.
Crossref
Crossref
Mitesh Patel & Dominick Shaw. (2015) A review of standard pharmacological therapy for adult asthma – Steps 1 to 5. Chronic Respiratory Disease 12:2, pages 165-176.
Crossref
Crossref
Alberto Papi, David Price, Joaquin Sastre, Kirsten Kaiser, Mark Lomax, Tammy McIver & Sanjeeva Dissanayake. (2015) Efficacy of fluticasone propionate/formoterol fumarate in the treatment of asthma: A pooled analysis. Respiratory Medicine 109:2, pages 208-217.
Crossref
Crossref
P. Devillier, H. Salvator, S. Grassin-Delyle, E. Naline, C. Advenier & N. Roche. (2014) Une nouvelle association fixe de fluticasone/formotérol dans un aérosol-doseur pressurisé pour le traitement de l’asthme. Revue des Maladies Respiratoires 31:8, pages 700-713.
Crossref
Crossref
A. Papi, F. Blasi, G.W. Canonica, M. Cazzola, S. Centanni, M.P. Foschino Barbaro, A.S. Melani, P. Paggiaro, F. Ricciardolo, A. Rossi & N. Scichilone. (2014) Fluticasone propionate/formoterol: A fixed-combination therapy with flexible dosage. European Journal of Internal Medicine 25:8, pages 695-700.
Crossref
Crossref
Baljinder Johal, Markus Howald, Manfred Fischer, Jonathan Marshall & Geraldine Venthoye. (2013) Fine Particle Profile of Fluticasone Propionate/Formoterol Fumarate Versus Other Combination Products: the DIFFUSE Study. Combination Products in Therapy 3:1-2, pages 39-51.
Crossref
Crossref
Gillian M. Keating & Kate McKeage. (2013) Fluticasone propionate/formoterol fumarate: a guide to its use in persistent asthma. Drugs & Therapy Perspectives 29:11, pages 342-347.
Crossref
Crossref
A. Cukier, C.M.A. Jacob, N.A. Rosario Filho, J. Fiterman, E.O. Vianna, J.L. Hetzel, M.A. Neis, E. Fiss, F.F.M. Castro, A.L.G. Fernandes, R. Stirbulov & E. Pizzichini. (2013) Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma. Respiratory Medicine 107:9, pages 1330-1338.
Crossref
Crossref
Sukhbir K Shahid. (2013) Newer glucocorticosteroids and corticosteroid resistance reversal in asthma. Pharmaceutical Patent Analyst 2:3, pages 373-385.
Crossref
Crossref
Sanjeeva Dissanayake, Birgit Grothe & Kirsten Kaiser. (2012) Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma. Respiratory Medicine 106, pages S20-S28.
Crossref
Crossref